Swerdlow, DI; Preiss, D; Kuchenbaecker, KB; Holmes, MV; Engmann, JE; Shah, T; Sofat, R; ... Sattar, N; + view all Swerdlow, DI; Preiss, D; Kuchenbaecker, KB; Holmes, MV; Engmann, JE; Shah, T; Sofat, R; Stender, S; Johnson, PC; Scott, RA; Leusink, M; Verweij, N; Sharp, SJ; Guo, Y; Giambartolomei, C; Chung, C; Peasey, A; Amuzu, A; Li, K; Palmen, J; Howard, P; Cooper, JA; Drenos, F; Li, YR; Lowe, G; Gallacher, J; Stewart, MC; Tzoulaki, I; Buxbaum, SG; van der A, DL; Forouhi, NG; Onland-Moret, NC; van der Schouw, YT; Schnabel, RB; Hubacek, JA; Kubinova, R; Baceviciene, M; Tamosiunas, A; Pajak, A; Topor-Madry, R; Stepaniak, U; Malyutina, S; Baldassarre, D; Sennblad, B; Tremoli, E; de Faire, U; Veglia, F; Ford, I; Jukema, JW; Westendorp, RG; de Borst, GJ; de Jong, PA; Algra, A; Spiering, W; der Zee, AH; Klungel, OH; de Boer, A; Doevendans, PA; Eaton, CB; Robinson, JG; Duggan, D; Kjekshus, J; Downs, JR; Gotto, AM; Keech, AC; Marchioli, R; Tognoni, G; Sever, PS; Poulter, NR; Waters, DD; Pedersen, TR; Amarenco, P; Nakamura, H; McMurray, JJ; Lewsey, JD; Chasman, DI; Ridker, PM; Maggioni, AP; Tavazzi, L; Ray, KK; Seshasai, SR; Manson, JE; Price, JF; Whincup, PH; Morris, RW; Lawlor, DA; Smith, GD; Ben-Shlomo, Y; Schreiner, PJ; Fornage, M; Siscovick, DS; Cushman, M; Kumari, M; Wareham, NJ; Verschuren, WM; Redline, S; Patel, SR; Whittaker, JC; Hamsten, A; Delaney, JA; Dale, C; Gaunt, TR; Wong, A; Kuh, D; Hardy, R; Kathiresan, S; Castillo, BA; van der Harst, P; Brunner, EJ; Tybjaerg-Hansen, A; Marmot, MG; Krauss, RM; Tsai, M; Coresh, J; Hoogeveen, RC; Psaty, BM; Lange, LA; Hakonarson, H; Dudbridge, F; Humphries, SE; Talmud, PJ; Kivimäki, M; Timpson, NJ; Langenberg, C; Asselbergs, FW; Voevoda, M; Bobak, M; Pikhart, H; Wilson, JG; Reiner, AP; Keating, BJ; Hingorani, AD; Sattar, N; - view fewer (2014) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet , 385 (9965) pp. 351-361. 10.1016/S0140-6736(14)61183-1.

PDF PIIS0140673614611831.pdf Download (779kB)

Abstract

Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item